Nektar Therapeutics (NKTR)

Market Cap	490.56M
Revenue (ttm)	95.04M
Net Income (ttm)	-454.16M
Shares Out	187.95M
EPS (ttm)	-2.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,789,974
Open	2.42
Previous Close	2.46
Day's Range	2.41 - 2.63
52-Week Range	1.99 - 11.59
Beta	0.92
Analysts	Sell
Price Target	4.50 (+72.41%)
Earnings Date	Feb 27, 2023

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell l...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Howard Robin
• Employees: 740
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR

Financial Performance

In 2021, NKTR's revenue was $101.91 million, a decrease of -33.36% compared to the previous year's $152.92 million. Losses were -$523.84 million, 17.9% more than in 2020.

Analyst Forecast

According to 15 analysts, the average rating for NKTR stock is "Sell." The 12-month stock price forecast is $4.5, which is an increase of 72.41% from the latest price.

Price Target

$4.5

(72.41% upside)

Analyst Consensus: Sell